(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 April 2010 (15.04.2010)

PCT

(10) International Publication Number
WO 2010/041051 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 47/32* (2006.01)

(21) International Application Number:
PCT/GB2009/051309

(22) International Filing Date:
5 October 2009 (05.10.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/103,347 7 October 2008 (07.10.2008) US

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BECHTOLD, Michael, Karl** [DE/DE]; Abbott GmbH & Co. KG, Knollstrasse 50, 67061 Ludwighafen (DE). **PACKHAEUSER, Claudia, Bettina** [DE/DE]; Abbott GmbH & Co. KG, Knollstrasse 50, 67061 Ludwighafen (DE). **CAHILL, Julie, Kay** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **FASTNACHT, Katja, Maren** [DE/DE]; Abbott GmbH & Co. KG, Knollstrasse 50, 67061 Ludwighafen (DE). **LIEPOLD, Bernd, Harald** [DE/DE]; Abbott GmbH & Co. KG, Knollstrasse 50, 67061 Ludwighafen (DE). **LENNON, Kieran, James** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). **STEITZ, Benedikt** [DE/DE]; Abbott GmbH & Co. KG, Knollstrasse 50, 67061 Ludwighafen (DE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; S-SE-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

WO 2010/041051 A1

(54) Title: PHARMACEUTICAL FORMULATION 514

Figure 2



(57) Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one for increasing the bioavailability of the drug.